Revenue growth of 5% First-quarter 2017 revenues Continuous strong growth in theranostics sales: +27% Theranostics revenues up to 50% of total sales In thousands of euros Three months to March 31, 2017 Three months to March 31, 2016 Change Croissy-Beaubourg and Montpellier, April 27, 2017, 8:00am CEST - THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME plans), a company specialized in in vitro diagnostics and theranostics, has today announced its consolidated first-quarter 2017 revenues. Revenues 2,297 2,185 +5% o/w Lisa Tracker® revenues 1,148 903 +27% o/w IVD revenues 1,149 1,282 -10% In the first...
|
